Patents Assigned to Amgen
  • TREATMENT OF OVARIAN CANCER USING A SPECIFIC BINDING AGENT OF HUMAN ANGIOPOIETIN-2 IN COMBINATION WITH A TAXANE
    Publication number: 20120183546
    Abstract: Methods and compositions for treating ovarian cancer in a patient comprising administering a therapeutically effective amount of an Angiopoictin-2 inhibitor in combination with a taxane.
    Type: Application
    Filed: September 23, 2010
    Publication date: July 19, 2012
    Applicant: AMGEN INC.
    Inventor: David M. Weinreich
  • ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY
    Publication number: 20120183561
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
    Patent number: 8221749
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: July 17, 2012
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Jonathan D. Oliner
  • Pyridopyridazine compounds, compositions and methods of use
    Patent number: 8222251
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: July 17, 2012
    Assignee: Amgen Inc.
    Inventors: Jacob Kaizerman, Brian Lucas, Dustin McMinn, Robert Zamboni
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120177646
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 12, 2012
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY
    Publication number: 20120177662
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 12, 2012
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120178685
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 12, 2012
    Applicant: Amgen Inc.
    Inventors: EDWARD JOHN BELOUSKI, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Fused heterocyclic derivatives and methods of use
    Patent number: 8217177
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: July 10, 2012
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, David Bauer, Steven Bellon, Christiane M. Bode, Alessandro Boezio, Deborah Choquette, Jean-Christophe Harmange, Julia Lohman, Michele Potashman
  • Methods and systems for isolating target molecules from complex solutions by column-chromatography using wash solutions containing organic solvents
    Patent number: 8217153
    Abstract: Various system and method embodiments of the present invention are directed to separating target molecules from complex solutions by affinity column chromatography using organic-solvent-containing eluants. In one embodiment of the present invention, an eluant containing an organic-solvent is used, at a first pH, to remove non-target solutes and suspended entities from an affinity chromatography column. The pH of the eluant is then changed to a second pH, and the organic-solvent-containing eluant is used to elute target molecules from the affinity column chromatography.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: July 10, 2012
    Assignee: Amgen Inc.
    Inventor: Joe Xin Hua Zhou
  • Fused heterocyclic derivatives and methods of use
    Patent number: 8212041
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: July 3, 2012
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, David Bauer, Steven Bellon, Christiane M. Bode, Alessandro Boezio, Deborah Choquette, Jean-Christophe Harmange, Julia Lohman, Michelle Potashman
  • Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors
    Publication number: 20120165334
    Abstract: The present invention provides compounds that are kinase inhibitors, specifically PIK kinase inhibitors, more specifically, mTOR inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PIK kinase inhibitors, more specifically, mTOR such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: February 10, 2010
    Publication date: June 28, 2012
    Applicant: AMGEN INC.
    Inventors: Alessandro Boezio, Alan C. Cheng, James Robert Coats, Katrina Woodin Copeland, Russell Graceffa, Jean-Christophe Harmanage, Hongbing Huang, Daniel La, Philip R. Olivieri, Emily Anne Peterson, Laurie Schenkel
  • Antibody categorization based on binding characteristics
    Patent number: 8206936
    Abstract: Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: June 26, 2012
    Assignee: Amgen Inc.
    Inventors: Wynn L. Walker, Michael L. Gallo, Xiao-Chi Jia, Keith Joho, Jaspal Singh Kang
  • Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
    Publication number: 20120156725
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: January 27, 2012
    Publication date: June 21, 2012
    Applicants: MEDAREX, INC., AMGEN INC.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Nucleic acid molecules that encode human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
    Patent number: 8202976
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: June 19, 2012
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng (Luke) Li, Haichun Huang
  • FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
    Publication number: 20120148531
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: December 1, 2011
    Publication date: June 14, 2012
    Applicant: Amgen Inc.
    Inventors: Brian K. ALBRECHT, David Bauer, Steven Bellon, Christiane M. Bode, Shon Booker, Alessandro Boezio, Deborah Choquette, Derin D'Amico, Jean-Christophe Harmange, Satoko Hirai, Randall W. Hungate, Tae-Seong Kim, Richard T. Lewis, Longbin Liu, Julia Lohman, Mark H. Norman, Michele Potashman, Aaron C. Siegmund, Stephanie Springer, Markian Stec, Ning Xi, Kevin Yang
  • HUMAN MONOCLONAL ANTIBODIES TO CTLA-4
    Publication number: 20120148597
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: February 17, 2012
    Publication date: June 14, 2012
    Applicants: Pfizer Inc., Amgen Fremont Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Patent number: 8198410
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: June 12, 2012
    Assignee: Amgen Inc.
    Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Fused heterocyclic derivatives and methods of use
    Patent number: 8198448
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: June 12, 2012
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, David Bauer, Alessandro Boezio, Deborah Choquette, Jean-Christophe Harmange, Richard T. Lewis, Julia Lohman, Michelle Potashman, Emily A. Peterson, Katrina W. Copeland, Karina Romero
  • Reducing the risk of human anti-human antibodies through V gene manipulation
    Patent number: 8198508
    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. Some embodiments herein are directed to transgenic mouse embodiments relevant for HAHA responses.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: June 12, 2012
    Assignee: Amgen Fremont, Inc.
    Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
  • METHODS OF TREATING PSORIASIS
    Publication number: 20120142605
    Abstract: The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid.
    Type: Application
    Filed: May 5, 2010
    Publication date: June 7, 2012
    Applicant: Amgen Inc.
    Inventors: Michele M. Hooper, Elizabeth H.Z. Thompson